<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01193101</url>
  </required_header>
  <id_info>
    <org_study_id>CLCZ696A2219</org_study_id>
    <nct_id>NCT01193101</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of LCZ696 Compared to Placebo in Patients With Essential Hypertension</brief_title>
  <official_title>A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study to Evaluate the Efficacy and Safety of LCZ696 Compared to Placebo After 8 Weeks Treatment in Patients With Essential Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study is a phase 2 study in patients with essential hypertension.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP)</measure>
    <time_frame>Baseline, 8 weeks</time_frame>
    <description>Sitting BP measurements were performed at screening through the end of the study at every study visit. A negative change from baseline indicates improvement.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP)</measure>
    <time_frame>Baseline, 8 weeks</time_frame>
    <description>Sitting BP measurements were performed at screening through the end of the study at every study visit. A negative change from baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 24 Hour Mean Ambulatory DBP and SBP</measure>
    <time_frame>Baseline, 8 weeks</time_frame>
    <description>Hourly mean ambulatory DBP and SBP post-dosing was calculated for each post-dosing hour over 24 hours by taking the average of the readings taken in the corresponding post-dosing hour at randomization and at week 8. A negative change from baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Daytime Mean Ambulatory DBP and SBP</measure>
    <time_frame>Baseline, 8 weeks</time_frame>
    <description>Hourly mean ambulatory DBP and SBP post-dosing was calculated for each post-dosing hour over 24 hours by taking the average of the readings taken in the corresponding post-dosing hour at randomization and at week 8. Daytime mean SBP and DBP were the averages of the hourly means between 6 am and 10 pm. A negative change from baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Nighttime Mean Ambulatory DBP and SBP</measure>
    <time_frame>Baseline, 8 weeks</time_frame>
    <description>Hourly mean ambulatory DBP and SBP post-dosing was calculated for each post-dosing hour over 24 hours by taking the average of the readings taken in the corresponding post-dosing hour at randomization and at week 8. Nighttime mean SBP and DBP were the averages of the hourly means between 10 pm and 6 am. A negative change from baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Sitting Pulse Pressure</measure>
    <time_frame>Baseline, 8 weeks</time_frame>
    <description>Mean sitting pulse pressure is the difference in msSBP and msDBP (msSBP - msDBP). A negative change from baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Ambulatory Pulse Pressure</measure>
    <time_frame>Baseline, 8 weeks</time_frame>
    <description>Mean ambulatory pulse pressure is the difference in maSBP and maDBP (maSBP - maDBP). A negative change from baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Achieved a Successful Response in msDBP</measure>
    <time_frame>8 weeks</time_frame>
    <description>Successful response in msDBP is defined as msDBP &lt;90 mmHg or a reduction ≥ 10 mmHg from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Achieved a Successful Response in msSBP</measure>
    <time_frame>8 weeks</time_frame>
    <description>Successful response in msSBP is defined as msSBP &lt;140 mmHg or a reduction ≥ 20 mmHg from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Achieved Successful BP Control</measure>
    <time_frame>8 weeks</time_frame>
    <description>BP control is defined as BP &lt; 140/90 mmHg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough to Post-dosing Hour Ratio for Change From Baseline in 24-hour Mean Ambulatory DBP</measure>
    <time_frame>baseline, 8 weeks</time_frame>
    <description>Trough to post-dosing hour ratio at each post-dosing hour = [trough LSM of LCZ696 - trough LSM of placebo]/[post-dosing hour LSM of LCZ696 - post-dosing hour LSM of placebo]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough to Post-dosing Hour Ratio for Change From Baseline in 24-hour Mean Ambulatory SBP</measure>
    <time_frame>baseline, 8 weeks</time_frame>
    <description>Trough to post-dosing hour ratio at each post-dosing hour = [trough LSM of LCZ696 - trough LSM of placebo]/[post-dosing hour LSM of LCZ696 - post-dosing hour LSM of placebo]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Week 8 to Week 9 in msDBP and msSBP After Single-blind Placebo Withdrawal at Week 8</measure>
    <time_frame>8 weeks, 9 weeks</time_frame>
    <description>From week 8 to week 9, participants entered a single-blind placebo withdrawal period to assess the effect of LCZ696 on blood pressure following its discontinuation. Participants, who were randomized to the LCZ696 treatment groups, were discontinued from CLCZ696 at the end of week 8 and all 4 treatment groups received single-blind placebo for 1 week post week 8. A positive change from week 8 to week 9 indicates worsening.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">389</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>LCZ696 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LCZ696 100 mg plus placebo daily during double blind (DB) treatment for 8 weeks and then single-blind placebo for one week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LCZ696 200 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LCZ696 200 mg plus placebo daily during double blind (DB) treatment for 8 weeks and then single-blind placebo for one week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LCZ696 400 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LCZ696 200 mg LCZ696 plus placebo for one week, then titrated up to 400 mg plus placebo for the remaining 7 weeks during DB treatment, and then single-blind placebo for one week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo daily for 8 weeks during DB treatment, and then single-blind placebo for 1 week.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LCZ696</intervention_name>
    <description>LCZ696</description>
    <arm_group_label>LCZ696 100 mg</arm_group_label>
    <arm_group_label>LCZ696 200 mg</arm_group_label>
    <arm_group_label>LCZ696 400 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>matching placebo to LCZ696</description>
    <arm_group_label>LCZ696 100 mg</arm_group_label>
    <arm_group_label>LCZ696 200 mg</arm_group_label>
    <arm_group_label>LCZ696 400 mg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients must give written informed consent before any assessment is performed.

          2. Patients with mild to moderate essential hypertension, untreated or currently taking
             antihypertensive therapy (mean sitting diastolic blood pressure ≥ 95 mmHg and &lt; 110
             mmHg, and mean sitting systolic blood pressure ≥ 140 mmHg and &lt; 180 mmHg).

          3. Patients must be willing and able to undergo ambulatory blood pressure monitoring for
             a 24-hr period at the beginning and the end of the 8-week treatment.

          4. Patient must be able to communicate and comply with all study requirements and
             demonstrate good medication compliance.

        Exclusion Criteria:

          1. Patients with severe hypertension.

          2. Patients with history of angioedema, drug-related or otherwise

          3. Pregnant or nursing women

          4. Women of child-bearing potential , who do not use adequate birth control methods

          5. History or evidence of a secondary form of hypertension.

          6. History of angina pectoris, myocardial infarction, coronary bypass surgery, ischemic
             heart disease, surgical or percutaneous arterial intervention of any kind, stroke,
             TIA, carotid artery stenosis, aortic aneurysm, or peripheral arterial disease.

          7. Diabetes mellitus.

          8. Previous or current diagnosis of heart failure (NYHA Class II-IV).

          9. Clinically significant valvular heart disease at the time of screening.

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <zip>050000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300142</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310009</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Beijing</city>
        <zip>100044</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Beijing</city>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chongqing</city>
        <zip>400042</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Yokohama-city</city>
        <state>Kanagawa</state>
        <zip>231-0023</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shimotsuke-city</city>
        <state>Tochigi</state>
        <zip>329-0498</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bunkyo-ku</city>
        <state>Tokyo</state>
        <zip>113-0031</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bunkyo-ku</city>
        <state>Tokyo</state>
        <zip>113-8655</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chiyoda-ku</city>
        <state>Tokyo</state>
        <zip>100-0005</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kiyose-city</city>
        <state>Tokyo</state>
        <zip>204-0021</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kunitachi</city>
        <state>Tokyo</state>
        <zip>186-0001</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Minato-ku</city>
        <state>Tokyo</state>
        <zip>105-7390</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Minato-ku</city>
        <state>Tokyo</state>
        <zip>108-0075</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ota-ku</city>
        <state>Tokyo</state>
        <zip>143-0023</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shinagawa-ku</city>
        <state>Tokyo</state>
        <zip>141-0032</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shinagawa-ku</city>
        <state>Tokyo</state>
        <zip>142-0053</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shinagawa-ku</city>
        <state>Tokyo</state>
        <zip>142-0063</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toshima-ku</city>
        <state>Tokyo</state>
        <zip>171-0021</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bucheon</city>
        <state>Gyeonggi-do</state>
        <zip>424-717</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <state>Korea</state>
        <zip>137-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Koyang</city>
        <state>Kyunggi</state>
        <zip>410-719</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Daegu</city>
        <zip>705-703</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <zip>150-950</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <zip>152-703</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Changhua</city>
        <zip>500</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taichung</city>
        <zip>40447</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taipei</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taipei</city>
        <zip>10449</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taipei</city>
        <zip>114</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chiang Mai</city>
        <zip>50200</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Taiwan</country>
    <country>Thailand</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 26, 2010</study_first_submitted>
  <study_first_submitted_qc>August 30, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 1, 2010</study_first_posted>
  <results_first_submitted>July 23, 2015</results_first_submitted>
  <results_first_submitted_qc>July 23, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 19, 2015</results_first_posted>
  <last_update_submitted>January 13, 2016</last_update_submitted>
  <last_update_submitted_qc>January 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hypertension</keyword>
  <keyword>blood pressure</keyword>
  <keyword>LCZ696</keyword>
  <keyword>dual-acting</keyword>
  <keyword>neprilysin</keyword>
  <keyword>nep inhibitor</keyword>
  <keyword>vasopeptidase</keyword>
  <keyword>angiotensin receptor</keyword>
  <keyword>ARNi</keyword>
  <keyword>Essential hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>LCZ 696</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study comprised 3 periods: a 4 week washout and placebo run-in period, an 8 week randomized, double-blind period and a 1 week single-blind, placebo withdrawal period.</recruitment_details>
      <pre_assignment_details>In the run-in period, 457 participants were enrolled. Of the 457 participants, 389 participants were eligible for randomization and randomized in a 1:1:1:1 ratio to each treatment group.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>LCZ696 100 mg</title>
          <description>LCZ696 100 mg plus placebo daily during double blind (DB) treatment for 8 weeks and then single-blind placebo for one week.</description>
        </group>
        <group group_id="P2">
          <title>LCZ696 200 mg</title>
          <description>LCZ696 200 mg plus placebo daily during double blind (DB) treatment for 8 weeks and then single-blind placebo for one week.</description>
        </group>
        <group group_id="P3">
          <title>LCZ696 400 mg</title>
          <description>LCZ696 200 mg LCZ696 plus placebo for one week, then titrated up to 400 mg plus placebo for the remaining 7 weeks during DB treatment, and then single-blind placebo for one week.</description>
        </group>
        <group group_id="P4">
          <title>Placebo</title>
          <description>Placebo daily for 8 weeks during DB treatment, and then single-blind placebo for 1 week.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="100"/>
                <participants group_id="P2" count="101"/>
                <participants group_id="P3" count="96"/>
                <participants group_id="P4" count="92"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Full Analysis Set</title>
              <participants_list>
                <participants group_id="P1" count="100"/>
                <participants group_id="P2" count="101"/>
                <participants group_id="P3" count="96"/>
                <participants group_id="P4" count="92"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Placebo Withdrawal Set</title>
              <participants_list>
                <participants group_id="P1" count="95"/>
                <participants group_id="P2" count="94"/>
                <participants group_id="P3" count="93"/>
                <participants group_id="P4" count="80"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="95"/>
                <participants group_id="P2" count="94"/>
                <participants group_id="P3" count="93"/>
                <participants group_id="P4" count="80"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="12"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative problems</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Abnormal test procedure results</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>LCZ696 100 mg</title>
          <description>LCZ696 100 mg plus placebo daily during double blind (DB) treatment for 8 weeks and then single-blind placebo for one week.</description>
        </group>
        <group group_id="B2">
          <title>LCZ696 200 mg</title>
          <description>LCZ696 200 mg plus placebo daily during double blind (DB) treatment for 8 weeks and then single-blind placebo for one week.</description>
        </group>
        <group group_id="B3">
          <title>LCZ696 400 mg</title>
          <description>LCZ696 200 mg LCZ696 plus placebo for one week, then titrated up to 400 mg plus placebo for the remaining 7 weeks during DB treatment, and then single-blind placebo for one week.</description>
        </group>
        <group group_id="B4">
          <title>Placebo</title>
          <description>Placebo daily for 8 weeks during DB treatment, and then single-blind placebo for 1 week.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="100"/>
            <count group_id="B2" value="101"/>
            <count group_id="B3" value="96"/>
            <count group_id="B4" value="92"/>
            <count group_id="B5" value="389"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.5" spread="10.03"/>
                    <measurement group_id="B2" value="52.1" spread="8.82"/>
                    <measurement group_id="B3" value="50.9" spread="9.81"/>
                    <measurement group_id="B4" value="50.9" spread="10.65"/>
                    <measurement group_id="B5" value="51.6" spread="9.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="24"/>
                    <measurement group_id="B5" value="114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="74"/>
                    <measurement group_id="B3" value="73"/>
                    <measurement group_id="B4" value="68"/>
                    <measurement group_id="B5" value="275"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP)</title>
        <description>Sitting BP measurements were performed at screening through the end of the study at every study visit. A negative change from baseline indicates improvement.</description>
        <time_frame>Baseline, 8 weeks</time_frame>
        <population>Participants from the full analysis set (FAS), who had both baseline and week 8 values, were analyzed. The FAS included all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>LCZ696 100 mg</title>
            <description>LCZ696 100 mg plus placebo daily during double blind (DB) treatment for 8 weeks and then single-blind placebo for one week.</description>
          </group>
          <group group_id="O2">
            <title>LCZ696 200 mg</title>
            <description>LCZ696 200 mg plus placebo daily during double blind (DB) treatment for 8 weeks and then single-blind placebo for one week.</description>
          </group>
          <group group_id="O3">
            <title>LCZ696 400 mg</title>
            <description>LCZ696 200 mg LCZ696 plus placebo for one week, then titrated up to 400 mg plus placebo for the remaining 7 weeks during DB treatment, and then single-blind placebo for one week.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo daily for 8 weeks during DB treatment, and then single-blind placebo for 1 week.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP)</title>
          <description>Sitting BP measurements were performed at screening through the end of the study at every study visit. A negative change from baseline indicates improvement.</description>
          <population>Participants from the full analysis set (FAS), who had both baseline and week 8 values, were analyzed. The FAS included all randomized participants.</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="98"/>
                <count group_id="O3" value="96"/>
                <count group_id="O4" value="92"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.53" spread="0.88"/>
                    <measurement group_id="O2" value="-10.98" spread="0.89"/>
                    <measurement group_id="O3" value="-12.45" spread="0.90"/>
                    <measurement group_id="O4" value="-3.69" spread="0.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP)</title>
        <description>Sitting BP measurements were performed at screening through the end of the study at every study visit. A negative change from baseline indicates improvement.</description>
        <time_frame>Baseline, 8 weeks</time_frame>
        <population>Participants from the full analysis set (FAS), who had both baseline and week 8 values, were analyzed. The FAS included all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>LCZ696 100 mg</title>
            <description>LCZ696 100 mg plus placebo daily during double blind (DB) treatment for 8 weeks and then single-blind placebo for one week.</description>
          </group>
          <group group_id="O2">
            <title>LCZ696 200 mg</title>
            <description>LCZ696 200 mg plus placebo daily during double blind (DB) treatment for 8 weeks and then single-blind placebo for one week.</description>
          </group>
          <group group_id="O3">
            <title>LCZ696 400 mg</title>
            <description>LCZ696 200 mg LCZ696 plus placebo for one week, then titrated up to 400 mg plus placebo for the remaining 7 weeks during DB treatment, and then single-blind placebo for one week.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo daily for 8 weeks during DB treatment, and then single-blind placebo for 1 week.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP)</title>
          <description>Sitting BP measurements were performed at screening through the end of the study at every study visit. A negative change from baseline indicates improvement.</description>
          <population>Participants from the full analysis set (FAS), who had both baseline and week 8 values, were analyzed. The FAS included all randomized participants.</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="98"/>
                <count group_id="O3" value="96"/>
                <count group_id="O4" value="92"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.83" spread="1.25"/>
                    <measurement group_id="O2" value="-17.54" spread="1.27"/>
                    <measurement group_id="O3" value="-20.35" spread="1.28"/>
                    <measurement group_id="O4" value="-4.97" spread="1.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 24 Hour Mean Ambulatory DBP and SBP</title>
        <description>Hourly mean ambulatory DBP and SBP post-dosing was calculated for each post-dosing hour over 24 hours by taking the average of the readings taken in the corresponding post-dosing hour at randomization and at week 8. A negative change from baseline indicates improvement.</description>
        <time_frame>Baseline, 8 weeks</time_frame>
        <population>Participants from the full analysis set (FAS), who had both baseline and week 8 values, were analyzed. The FAS included all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>LCZ696 100 mg</title>
            <description>LCZ696 100 mg plus placebo daily during double blind (DB) treatment for 8 weeks and then single-blind placebo for one week.</description>
          </group>
          <group group_id="O2">
            <title>LCZ696 200 mg</title>
            <description>LCZ696 200 mg plus placebo daily during double blind (DB) treatment for 8 weeks and then single-blind placebo for one week.</description>
          </group>
          <group group_id="O3">
            <title>LCZ696 400 mg</title>
            <description>LCZ696 200 mg LCZ696 plus placebo for one week, then titrated up to 400 mg plus placebo for the remaining 7 weeks during DB treatment, and then single-blind placebo for one week.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo daily for 8 weeks during DB treatment, and then single-blind placebo for 1 week.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 24 Hour Mean Ambulatory DBP and SBP</title>
          <description>Hourly mean ambulatory DBP and SBP post-dosing was calculated for each post-dosing hour over 24 hours by taking the average of the readings taken in the corresponding post-dosing hour at randomization and at week 8. A negative change from baseline indicates improvement.</description>
          <population>Participants from the full analysis set (FAS), who had both baseline and week 8 values, were analyzed. The FAS included all randomized participants.</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="84"/>
                <count group_id="O3" value="82"/>
                <count group_id="O4" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>maDBP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.34" spread="0.50"/>
                    <measurement group_id="O2" value="-9.33" spread="0.49"/>
                    <measurement group_id="O3" value="-9.69" spread="0.50"/>
                    <measurement group_id="O4" value="0.28" spread="0.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>maSBP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.07" spread="0.65"/>
                    <measurement group_id="O2" value="-15.18" spread="0.64"/>
                    <measurement group_id="O3" value="-15.98" spread="0.65"/>
                    <measurement group_id="O4" value="0.19" spread="0.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Daytime Mean Ambulatory DBP and SBP</title>
        <description>Hourly mean ambulatory DBP and SBP post-dosing was calculated for each post-dosing hour over 24 hours by taking the average of the readings taken in the corresponding post-dosing hour at randomization and at week 8. Daytime mean SBP and DBP were the averages of the hourly means between 6 am and 10 pm. A negative change from baseline indicates improvement.</description>
        <time_frame>Baseline, 8 weeks</time_frame>
        <population>Participants from the full analysis set (FAS), who had both baseline and week 8 values, were analyzed. The FAS included all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>LCZ696 100 mg</title>
            <description>LCZ696 100 mg plus placebo daily during double blind (DB) treatment for 8 weeks and then single-blind placebo for one week.</description>
          </group>
          <group group_id="O2">
            <title>LCZ696 200 mg</title>
            <description>LCZ696 200 mg plus placebo daily during double blind (DB) treatment for 8 weeks and then single-blind placebo for one week.</description>
          </group>
          <group group_id="O3">
            <title>LCZ696 400 mg</title>
            <description>LCZ696 200 mg LCZ696 plus placebo for one week, then titrated up to 400 mg plus placebo for the remaining 7 weeks during DB treatment, and then single-blind placebo for one week.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo daily for 8 weeks during DB treatment, and then single-blind placebo for 1 week.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Daytime Mean Ambulatory DBP and SBP</title>
          <description>Hourly mean ambulatory DBP and SBP post-dosing was calculated for each post-dosing hour over 24 hours by taking the average of the readings taken in the corresponding post-dosing hour at randomization and at week 8. Daytime mean SBP and DBP were the averages of the hourly means between 6 am and 10 pm. A negative change from baseline indicates improvement.</description>
          <population>Participants from the full analysis set (FAS), who had both baseline and week 8 values, were analyzed. The FAS included all randomized participants.</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="84"/>
                <count group_id="O3" value="82"/>
                <count group_id="O4" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>maDBP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.46" spread="0.81"/>
                    <measurement group_id="O2" value="-8.65" spread="0.80"/>
                    <measurement group_id="O3" value="-9.77" spread="0.81"/>
                    <measurement group_id="O4" value="-0.13" spread="0.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>maSBP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.29" spread="1.08"/>
                    <measurement group_id="O2" value="-14.62" spread="1.06"/>
                    <measurement group_id="O3" value="-16.58" spread="1.08"/>
                    <measurement group_id="O4" value="0.01" spread="1.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Nighttime Mean Ambulatory DBP and SBP</title>
        <description>Hourly mean ambulatory DBP and SBP post-dosing was calculated for each post-dosing hour over 24 hours by taking the average of the readings taken in the corresponding post-dosing hour at randomization and at week 8. Nighttime mean SBP and DBP were the averages of the hourly means between 10 pm and 6 am. A negative change from baseline indicates improvement.</description>
        <time_frame>Baseline, 8 weeks</time_frame>
        <population>Participants from the full analysis set (FAS), who had both baseline and week 8 values, were analyzed. The FAS included all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>LCZ696 100 mg</title>
            <description>LCZ696 100 mg plus placebo daily during double blind (DB) treatment for 8 weeks and then single-blind placebo for one week.</description>
          </group>
          <group group_id="O2">
            <title>LCZ696 200 mg</title>
            <description>LCZ696 200 mg plus placebo daily during double blind (DB) treatment for 8 weeks and then single-blind placebo for one week.</description>
          </group>
          <group group_id="O3">
            <title>LCZ696 400 mg</title>
            <description>LCZ696 200 mg LCZ696 plus placebo for one week, then titrated up to 400 mg plus placebo for the remaining 7 weeks during DB treatment, and then single-blind placebo for one week.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo daily for 8 weeks during DB treatment, and then single-blind placebo for 1 week.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Nighttime Mean Ambulatory DBP and SBP</title>
          <description>Hourly mean ambulatory DBP and SBP post-dosing was calculated for each post-dosing hour over 24 hours by taking the average of the readings taken in the corresponding post-dosing hour at randomization and at week 8. Nighttime mean SBP and DBP were the averages of the hourly means between 10 pm and 6 am. A negative change from baseline indicates improvement.</description>
          <population>Participants from the full analysis set (FAS), who had both baseline and week 8 values, were analyzed. The FAS included all randomized participants.</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="83"/>
                <count group_id="O3" value="82"/>
                <count group_id="O4" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>maDBP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.96" spread="0.81"/>
                    <measurement group_id="O2" value="-10.36" spread="0.80"/>
                    <measurement group_id="O3" value="-9.47" spread="0.81"/>
                    <measurement group_id="O4" value="0.97" spread="0.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>maSBP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.27" spread="1.08"/>
                    <measurement group_id="O2" value="-16.14" spread="1.07"/>
                    <measurement group_id="O3" value="-14.65" spread="1.08"/>
                    <measurement group_id="O4" value="0.61" spread="1.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Sitting Pulse Pressure</title>
        <description>Mean sitting pulse pressure is the difference in msSBP and msDBP (msSBP - msDBP). A negative change from baseline indicates improvement.</description>
        <time_frame>Baseline, 8 weeks</time_frame>
        <population>Participants from the full analysis set (FAS), who had both baseline and week 8 values, were analyzed. The FAS included all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>LCZ696 100 mg</title>
            <description>LCZ696 100 mg plus placebo daily during double blind (DB) treatment for 8 weeks and then single-blind placebo for one week.</description>
          </group>
          <group group_id="O2">
            <title>LCZ696 200 mg</title>
            <description>LCZ696 200 mg plus placebo daily during double blind (DB) treatment for 8 weeks and then single-blind placebo for one week.</description>
          </group>
          <group group_id="O3">
            <title>LCZ696 400 mg</title>
            <description>LCZ696 200 mg LCZ696 plus placebo for one week, then titrated up to 400 mg plus placebo for the remaining 7 weeks during DB treatment, and then single-blind placebo for one week.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo daily for 8 weeks during DB treatment, and then single-blind placebo for 1 week.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Sitting Pulse Pressure</title>
          <description>Mean sitting pulse pressure is the difference in msSBP and msDBP (msSBP - msDBP). A negative change from baseline indicates improvement.</description>
          <population>Participants from the full analysis set (FAS), who had both baseline and week 8 values, were analyzed. The FAS included all randomized participants.</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="98"/>
                <count group_id="O3" value="96"/>
                <count group_id="O4" value="92"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.11" spread="0.81"/>
                    <measurement group_id="O2" value="-6.49" spread="0.83"/>
                    <measurement group_id="O3" value="-7.82" spread="0.83"/>
                    <measurement group_id="O4" value="-1.09" spread="0.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Ambulatory Pulse Pressure</title>
        <description>Mean ambulatory pulse pressure is the difference in maSBP and maDBP (maSBP - maDBP). A negative change from baseline indicates improvement.</description>
        <time_frame>Baseline, 8 weeks</time_frame>
        <population>Participants from the full analysis set (FAS), who had both baseline and week 8 values, were analyzed. The FAS included all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>LCZ696 100 mg</title>
            <description>LCZ696 100 mg plus placebo daily during double blind (DB) treatment for 8 weeks and then single-blind placebo for one week.</description>
          </group>
          <group group_id="O2">
            <title>LCZ696 200 mg</title>
            <description>LCZ696 200 mg plus placebo daily during double blind (DB) treatment for 8 weeks and then single-blind placebo for one week.</description>
          </group>
          <group group_id="O3">
            <title>LCZ696 400 mg</title>
            <description>LCZ696 200 mg LCZ696 plus placebo for one week, then titrated up to 400 mg plus placebo for the remaining 7 weeks during DB treatment, and then single-blind placebo for one week.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo daily for 8 weeks during DB treatment, and then single-blind placebo for 1 week.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Ambulatory Pulse Pressure</title>
          <description>Mean ambulatory pulse pressure is the difference in maSBP and maDBP (maSBP - maDBP). A negative change from baseline indicates improvement.</description>
          <population>Participants from the full analysis set (FAS), who had both baseline and week 8 values, were analyzed. The FAS included all randomized participants.</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="84"/>
                <count group_id="O3" value="82"/>
                <count group_id="O4" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.68" spread="0.30"/>
                    <measurement group_id="O2" value="-5.84" spread="0.29"/>
                    <measurement group_id="O3" value="-6.31" spread="0.30"/>
                    <measurement group_id="O4" value="-0.08" spread="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Achieved a Successful Response in msDBP</title>
        <description>Successful response in msDBP is defined as msDBP &lt;90 mmHg or a reduction ≥ 10 mmHg from baseline.</description>
        <time_frame>8 weeks</time_frame>
        <population>Participants from the full analysis set (FAS), who had week 8 values, were analyzed. The FAS included all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>LCZ696 100 mg</title>
            <description>LCZ696 100 mg plus placebo daily during double blind (DB) treatment for 8 weeks and then single-blind placebo for one week.</description>
          </group>
          <group group_id="O2">
            <title>LCZ696 200 mg</title>
            <description>LCZ696 200 mg plus placebo daily during double blind (DB) treatment for 8 weeks and then single-blind placebo for one week.</description>
          </group>
          <group group_id="O3">
            <title>LCZ696 400 mg</title>
            <description>LCZ696 200 mg LCZ696 plus placebo for one week, then titrated up to 400 mg plus placebo for the remaining 7 weeks during DB treatment, and then single-blind placebo for one week.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo daily for 8 weeks during DB treatment, and then single-blind placebo for 1 week.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Achieved a Successful Response in msDBP</title>
          <description>Successful response in msDBP is defined as msDBP &lt;90 mmHg or a reduction ≥ 10 mmHg from baseline.</description>
          <population>Participants from the full analysis set (FAS), who had week 8 values, were analyzed. The FAS included all randomized participants.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="98"/>
                <count group_id="O3" value="96"/>
                <count group_id="O4" value="92"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                    <measurement group_id="O2" value="64"/>
                    <measurement group_id="O3" value="67"/>
                    <measurement group_id="O4" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Achieved a Successful Response in msSBP</title>
        <description>Successful response in msSBP is defined as msSBP &lt;140 mmHg or a reduction ≥ 20 mmHg from baseline.</description>
        <time_frame>8 weeks</time_frame>
        <population>Participants from the full analysis set (FAS), who had week 8 values, were analyzed. The FAS included all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>LCZ696 100 mg</title>
            <description>LCZ696 100 mg plus placebo daily during double blind (DB) treatment for 8 weeks and then single-blind placebo for one week.</description>
          </group>
          <group group_id="O2">
            <title>LCZ696 200 mg</title>
            <description>LCZ696 200 mg plus placebo daily during double blind (DB) treatment for 8 weeks and then single-blind placebo for one week.</description>
          </group>
          <group group_id="O3">
            <title>LCZ696 400 mg</title>
            <description>LCZ696 200 mg LCZ696 plus placebo for one week, then titrated up to 400 mg plus placebo for the remaining 7 weeks during DB treatment, and then single-blind placebo for one week.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo daily for 8 weeks during DB treatment, and then single-blind placebo for 1 week.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Achieved a Successful Response in msSBP</title>
          <description>Successful response in msSBP is defined as msSBP &lt;140 mmHg or a reduction ≥ 20 mmHg from baseline.</description>
          <population>Participants from the full analysis set (FAS), who had week 8 values, were analyzed. The FAS included all randomized participants.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="98"/>
                <count group_id="O3" value="96"/>
                <count group_id="O4" value="92"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                    <measurement group_id="O2" value="62"/>
                    <measurement group_id="O3" value="66"/>
                    <measurement group_id="O4" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Achieved Successful BP Control</title>
        <description>BP control is defined as BP &lt; 140/90 mmHg.</description>
        <time_frame>8 weeks</time_frame>
        <population>Participants from the full analysis set (FAS), who had week 8 values, were analyzed. The FAS included all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>LCZ696 100 mg</title>
            <description>LCZ696 100 mg plus placebo daily during double blind (DB) treatment for 8 weeks and then single-blind placebo for one week.</description>
          </group>
          <group group_id="O2">
            <title>LCZ696 200 mg</title>
            <description>LCZ696 200 mg plus placebo daily during double blind (DB) treatment for 8 weeks and then single-blind placebo for one week.</description>
          </group>
          <group group_id="O3">
            <title>LCZ696 400 mg</title>
            <description>LCZ696 200 mg LCZ696 plus placebo for one week, then titrated up to 400 mg plus placebo for the remaining 7 weeks during DB treatment, and then single-blind placebo for one week.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo daily for 8 weeks during DB treatment, and then single-blind placebo for 1 week.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Achieved Successful BP Control</title>
          <description>BP control is defined as BP &lt; 140/90 mmHg.</description>
          <population>Participants from the full analysis set (FAS), who had week 8 values, were analyzed. The FAS included all randomized participants.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="98"/>
                <count group_id="O3" value="96"/>
                <count group_id="O4" value="92"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="48"/>
                    <measurement group_id="O3" value="52"/>
                    <measurement group_id="O4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough to Post-dosing Hour Ratio for Change From Baseline in 24-hour Mean Ambulatory DBP</title>
        <description>Trough to post-dosing hour ratio at each post-dosing hour = [trough LSM of LCZ696 - trough LSM of placebo]/[post-dosing hour LSM of LCZ696 - post-dosing hour LSM of placebo]</description>
        <time_frame>baseline, 8 weeks</time_frame>
        <population>Full Analysis Set (FAS): The FAS included all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>LCZ696 100 mg</title>
            <description>LCZ696 100 mg plus placebo daily during double blind (DB) treatment for 8 weeks and then single-blind placebo for one week.</description>
          </group>
          <group group_id="O2">
            <title>LCZ696 200 mg</title>
            <description>LCZ696 200 mg plus placebo daily during double blind (DB) treatment for 8 weeks and then single-blind placebo for one week.</description>
          </group>
          <group group_id="O3">
            <title>LCZ696 400 mg</title>
            <description>LCZ696 200 mg LCZ696 plus placebo for one week, then titrated up to 400 mg plus placebo for the remaining 7 weeks during DB treatment, and then single-blind placebo for one week.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough to Post-dosing Hour Ratio for Change From Baseline in 24-hour Mean Ambulatory DBP</title>
          <description>Trough to post-dosing hour ratio at each post-dosing hour = [trough LSM of LCZ696 - trough LSM of placebo]/[post-dosing hour LSM of LCZ696 - post-dosing hour LSM of placebo]</description>
          <population>Full Analysis Set (FAS): The FAS included all randomized participants.</population>
          <units>ratio</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="98"/>
                <count group_id="O3" value="96"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hour 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.95"/>
                    <measurement group_id="O2" value="1.32"/>
                    <measurement group_id="O3" value="1.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.76"/>
                    <measurement group_id="O2" value="1.03"/>
                    <measurement group_id="O3" value="0.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.64"/>
                    <measurement group_id="O2" value="1.35"/>
                    <measurement group_id="O3" value="0.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.77"/>
                    <measurement group_id="O2" value="1.30"/>
                    <measurement group_id="O3" value="1.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.82"/>
                    <measurement group_id="O2" value="1.18"/>
                    <measurement group_id="O3" value="1.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.73"/>
                    <measurement group_id="O2" value="1.04"/>
                    <measurement group_id="O3" value="1.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.68"/>
                    <measurement group_id="O2" value="1.00"/>
                    <measurement group_id="O3" value="1.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.75"/>
                    <measurement group_id="O2" value="0.88"/>
                    <measurement group_id="O3" value="0.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.80"/>
                    <measurement group_id="O2" value="1.07"/>
                    <measurement group_id="O3" value="1.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.76"/>
                    <measurement group_id="O2" value="1.15"/>
                    <measurement group_id="O3" value="1.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.82"/>
                    <measurement group_id="O2" value="1.31"/>
                    <measurement group_id="O3" value="1.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.56"/>
                    <measurement group_id="O2" value="0.92"/>
                    <measurement group_id="O3" value="0.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.67"/>
                    <measurement group_id="O2" value="0.86"/>
                    <measurement group_id="O3" value="0.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.69"/>
                    <measurement group_id="O2" value="0.91"/>
                    <measurement group_id="O3" value="0.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.57"/>
                    <measurement group_id="O2" value="0.69"/>
                    <measurement group_id="O3" value="0.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.58"/>
                    <measurement group_id="O2" value="0.65"/>
                    <measurement group_id="O3" value="0.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.89"/>
                    <measurement group_id="O2" value="0.92"/>
                    <measurement group_id="O3" value="1.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.86"/>
                    <measurement group_id="O2" value="0.92"/>
                    <measurement group_id="O3" value="1.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 19</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.83"/>
                    <measurement group_id="O2" value="0.99"/>
                    <measurement group_id="O3" value="1.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.84"/>
                    <measurement group_id="O2" value="1.06"/>
                    <measurement group_id="O3" value="1.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.76"/>
                    <measurement group_id="O2" value="1.02"/>
                    <measurement group_id="O3" value="1.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.98"/>
                    <measurement group_id="O2" value="1.09"/>
                    <measurement group_id="O3" value="0.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 23</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.02"/>
                    <measurement group_id="O2" value="0.93"/>
                    <measurement group_id="O3" value="0.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00"/>
                    <measurement group_id="O2" value="1.00"/>
                    <measurement group_id="O3" value="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough to Post-dosing Hour Ratio for Change From Baseline in 24-hour Mean Ambulatory SBP</title>
        <description>Trough to post-dosing hour ratio at each post-dosing hour = [trough LSM of LCZ696 - trough LSM of placebo]/[post-dosing hour LSM of LCZ696 - post-dosing hour LSM of placebo]</description>
        <time_frame>baseline, 8 weeks</time_frame>
        <population>Full Analysis Set (FAS) The FAS included all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>LCZ696 100 mg</title>
            <description>LCZ696 100 mg plus placebo daily during double blind (DB) treatment for 8 weeks and then single-blind placebo for one week.</description>
          </group>
          <group group_id="O2">
            <title>LCZ696 200 mg</title>
            <description>LCZ696 200 mg plus placebo daily during double blind (DB) treatment for 8 weeks and then single-blind placebo for one week.</description>
          </group>
          <group group_id="O3">
            <title>LCZ696 400 mg</title>
            <description>LCZ696 200 mg LCZ696 plus placebo for one week, then titrated up to 400 mg plus placebo for the remaining 7 weeks during DB treatment, and then single-blind placebo for one week.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough to Post-dosing Hour Ratio for Change From Baseline in 24-hour Mean Ambulatory SBP</title>
          <description>Trough to post-dosing hour ratio at each post-dosing hour = [trough LSM of LCZ696 - trough LSM of placebo]/[post-dosing hour LSM of LCZ696 - post-dosing hour LSM of placebo]</description>
          <population>Full Analysis Set (FAS) The FAS included all randomized participants.</population>
          <units>ratio</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="98"/>
                <count group_id="O3" value="96"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hour 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.98"/>
                    <measurement group_id="O2" value="1.29"/>
                    <measurement group_id="O3" value="1.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.01"/>
                    <measurement group_id="O2" value="1.26"/>
                    <measurement group_id="O3" value="1.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.97"/>
                    <measurement group_id="O2" value="1.35"/>
                    <measurement group_id="O3" value="1.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.89"/>
                    <measurement group_id="O2" value="1.21"/>
                    <measurement group_id="O3" value="1.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.93"/>
                    <measurement group_id="O2" value="1.20"/>
                    <measurement group_id="O3" value="1.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.87"/>
                    <measurement group_id="O2" value="1.20"/>
                    <measurement group_id="O3" value="1.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.69"/>
                    <measurement group_id="O2" value="0.89"/>
                    <measurement group_id="O3" value="0.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.74"/>
                    <measurement group_id="O2" value="0.86"/>
                    <measurement group_id="O3" value="1.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.74"/>
                    <measurement group_id="O2" value="0.90"/>
                    <measurement group_id="O3" value="0.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.84"/>
                    <measurement group_id="O2" value="1.17"/>
                    <measurement group_id="O3" value="1.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.80"/>
                    <measurement group_id="O2" value="1.15"/>
                    <measurement group_id="O3" value="1.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.69"/>
                    <measurement group_id="O2" value="1.01"/>
                    <measurement group_id="O3" value="1.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.87"/>
                    <measurement group_id="O2" value="0.92"/>
                    <measurement group_id="O3" value="1.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.77"/>
                    <measurement group_id="O2" value="0.90"/>
                    <measurement group_id="O3" value="1.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.67"/>
                    <measurement group_id="O2" value="0.79"/>
                    <measurement group_id="O3" value="1.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.84"/>
                    <measurement group_id="O2" value="0.80"/>
                    <measurement group_id="O3" value="1.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.12"/>
                    <measurement group_id="O2" value="1.06"/>
                    <measurement group_id="O3" value="1.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.04"/>
                    <measurement group_id="O2" value="1.05"/>
                    <measurement group_id="O3" value="1.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 19</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.14"/>
                    <measurement group_id="O2" value="1.16"/>
                    <measurement group_id="O3" value="1.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.07"/>
                    <measurement group_id="O2" value="1.17"/>
                    <measurement group_id="O3" value="1.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.06"/>
                    <measurement group_id="O2" value="1.12"/>
                    <measurement group_id="O3" value="1.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.21"/>
                    <measurement group_id="O2" value="1.44"/>
                    <measurement group_id="O3" value="1.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 23</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00"/>
                    <measurement group_id="O2" value="1.06"/>
                    <measurement group_id="O3" value="1.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hour 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00"/>
                    <measurement group_id="O2" value="1.00"/>
                    <measurement group_id="O3" value="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Week 8 to Week 9 in msDBP and msSBP After Single-blind Placebo Withdrawal at Week 8</title>
        <description>From week 8 to week 9, participants entered a single-blind placebo withdrawal period to assess the effect of LCZ696 on blood pressure following its discontinuation. Participants, who were randomized to the LCZ696 treatment groups, were discontinued from CLCZ696 at the end of week 8 and all 4 treatment groups received single-blind placebo for 1 week post week 8. A positive change from week 8 to week 9 indicates worsening.</description>
        <time_frame>8 weeks, 9 weeks</time_frame>
        <population>Only participants from the full analysis, who had values at both week 8 and week 9, were included in the analysis. The FAS included all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>LCZ696 100 mg</title>
            <description>LCZ696 100 mg plus placebo daily during double blind (DB) treatment for 8 weeks and then single-blind placebo for one week.</description>
          </group>
          <group group_id="O2">
            <title>LCZ696 200 mg</title>
            <description>LCZ696 200 mg plus placebo daily during double blind (DB) treatment for 8 weeks and then single-blind placebo for one week.</description>
          </group>
          <group group_id="O3">
            <title>LCZ696 400 mg</title>
            <description>LCZ696 200 mg LCZ696 plus placebo for one week, then titrated up to 400 mg plus placebo for the remaining 7 weeks during DB treatment, and then single-blind placebo for one week.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo daily for 8 weeks during DB treatment, and then single-blind placebo for 1 week.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Week 8 to Week 9 in msDBP and msSBP After Single-blind Placebo Withdrawal at Week 8</title>
          <description>From week 8 to week 9, participants entered a single-blind placebo withdrawal period to assess the effect of LCZ696 on blood pressure following its discontinuation. Participants, who were randomized to the LCZ696 treatment groups, were discontinued from CLCZ696 at the end of week 8 and all 4 treatment groups received single-blind placebo for 1 week post week 8. A positive change from week 8 to week 9 indicates worsening.</description>
          <population>Only participants from the full analysis, who had values at both week 8 and week 9, were included in the analysis. The FAS included all randomized participants.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="95"/>
                <count group_id="O2" value="94"/>
                <count group_id="O3" value="93"/>
                <count group_id="O4" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>msDBP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8" spread="7.61"/>
                    <measurement group_id="O2" value="5.1" spread="7.03"/>
                    <measurement group_id="O3" value="5.6" spread="7.01"/>
                    <measurement group_id="O4" value="-0.6" spread="6.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>msSBP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0" spread="11.88"/>
                    <measurement group_id="O2" value="8.8" spread="11.62"/>
                    <measurement group_id="O3" value="11.6" spread="10.96"/>
                    <measurement group_id="O4" value="-0.7" spread="10.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>LCZ696 100 mg</title>
          <description>LCZ696 100 mg plus placebo daily during double blind (DB) treatment for 8 weeks and then single-blind placebo for one week.</description>
        </group>
        <group group_id="E2">
          <title>LCZ696 200 mg</title>
          <description>LCZ696 200 mg plus placebo daily during double blind (DB) treatment for 8 weeks and then single-blind placebo for one week.</description>
        </group>
        <group group_id="E3">
          <title>LCZ696 400 mg</title>
          <description>LCZ696 200 mg LCZ696 plus placebo for one week, then titrated up to 400 mg plus placebo for the remaining 7 weeks during DB treatment, and then single-blind placebo for one week.</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>Placebo daily for 8 weeks during DB treatment, and then single-blind placebo for 1 week.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="96"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dysarthria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="96"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="96"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="96"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="101"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="96"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>+1 (862) 778-1873</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

